Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1/2 study of Olvi-Vec in non small cell lung cancer (NSCLC)

Next Previous
Search
Trial Profile

A phase 1/2 study of Olvi-Vec in non small cell lung cancer (NSCLC)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olvimulogene nanivacirepvec (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Newsoara Biopharma

    • Most Recent Events

    • 13 Dec 2024 According to a Genelux Corporation media release, Company announces Thomas Zindrick (President, CEO, and Chairman) will join a virtual chat with H.C. Wainwright on December 16th. The discussion will cover the company's clinical program for Olvi-Vec, including its ongoing Phase 3 registration trial in platinum resistant/refractory ovarian cancer (PRROC), Phase 1b/2 trial in small-cell lung cancer (SCLC) and Phase 2 trial in non-small cell lung cancer.
    • 14 Aug 2024 According to a Genelux Corporation media release, the company anticipates an interim readout in the second half of 2024 for the Phase 1b part of the Phase 1b/2 trial in patients with recurrent small cell lung cancer in China and interim results from the Phase 2 trial in recurrent non-small cell lung cancer by mid-2025.
    • 18 Aug 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top